human igg2

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

Human Immunoglobulin G2 (Human IgG2) is a subclass of human IgG antibodies. An IgG2 deficiency can result in a diminished antibody response to bacterial polysaccharides, potentially increasing vulnerability to infections from encapsulated bacteria.

Human IgG2 kappa, Isotype Control is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which is engineered by combining the antigen-binding variable region derived from a mouse monoclonal antibody with the constant domain of a human IgG2 kappa immunoglobulin, thus serving as an immunological control for non-specific binding and Fc receptor interactions.

VHH-Human IgG2 Fc, Isotype Control is a VHH-Fc fusion isotype control based on human IgG2 Fc. It can be used as a negative control in immunology research.

Human IgG1 CH1-Human IgG2 Fc-Kappa Isotype control is the isotype control for Human IgG1 CH1+Human IgG2 Fc-Kappa antibody.

Human IgG2 lambda, Isotype Control is a human monoclonal antibody that serves as an isotype control for human IgG2 lambda antibodies.

Figitumumab (CP-751871) is a highly potent, fully human monoclonal antibody of the IgG2 isotype that specifically targets the insulin-like growth factor 1 receptor (IGF1R). it functions by competitively inhibiting the binding of IGF1 to its receptor with a IC50 of 1.8 nM. Figitumumab can be used in studies about advanced squamous cell carcinoma of the lung.

Brodalumab (AMG 827) is a human monoclonal IgG2 antibody targeting the interleukin 17 receptor (IL-17R), commonly used as an immunosuppressant in treating psoriasis.

Tarextumab (OMP-59R5) is a fully human IgG2 monoclonal antibody designed to selectively target and inhibit the signaling of Notch2 and Notch3 receptors. preclinical and clinical studies have demonstrated that inhibition of the Notch2/3 pathway with chemotherapeutic agents is efficacious across a broad spectrum of epithelial tumors, including breast, lung, ovarian, and pancreatic cancers, thereby establishing Tarextumab as a promising candidate for oncological research and development.

Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1 with a Kd value of 7 nM for human ALK1. It has an inhibitory effect on TGF-β and can be used to study hepatocellular carcinoma (HCC).

Befovacimab (BAY 1093884) is a fully human monoclonal antibody directed against tissue factor pathway inhibitor (TFPI). By blocking the inhibitory activity of TFPI on Factor Xa and the tissue factor-Factor VIIa (TF-VIIa) complex, it restores thrombin generation, holding significant potential for the treatment research of Hemophilia A and B.

Tafolecimab (IBI-306) is a humanised monoclonal antibody targeting PCSK9, capable of improving multiple lipid parameters (LDL, LDL-C, LDL-CFB, etc.), suitable for studying hypercholesterolaemia and mixed hyperlipidaemia.

Eflepedocokin alfa is a recombinant fusion protein comprising human IL-22 fused with the human IgG2-Fc domain, exhibiting cell protective activity. It activates the IL-22/IL-22R-mediated signal transduction pathways, including STAT3, playing a critical role in immune response to bacterial infections. It enhances intestinal barrier function, boosts intestinal immunity, and facilitates tissue repair [1].

Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).

Prezalumab (AMG 557) is a human IgG2 monoclonal antibody targeting ICOSL and BAFF, used for studying Sjogren's syndrome, cutaneous lupus erythematosus, psoriasis, systemic lupus erythematosus arthritis, and systemic lupus erythematosus (SLE).

Ivuxolimab is a fully human immunoglobulin G2 (IgG2) monoclonal antibody functioning as an agonist that targets the OX40 receptor (CD134), which selectively binds to the OX40 receptor expressed on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cellular cytotoxicity. Ivuxolimab can promote T cell proliferation, enhance cell survival, stimulate cytokine secretion (such as IFN-γ and IL-2), inhibit the suppressive function of regulatory T cells (Tregs), and potentiate anti-tumor immune responses, enabling its use in the study of cancers including melanoma, hepatocellular carcinoma, and head and neck squamous cell carcinoma.

Bapotulimab (BAY-1905254) is a human/mouse/monkey cross-reactive monoclonal antibody that targets and inhibits ILDR2 (immunoglobulin-like domain containing receptor 2), blocking its immunosuppressive activity for cancer immunotherapy. Bapotulimab promotes T-cell activation in mice, enhancing antigen-specific T-cell proliferation and cytotoxicity.

Fulranumab (AMG-403) is a humanised monoclonal antibody targeting nerve growth factor (NGF), which blocks the binding and activation of NGF with TrkA and p75NTR and has analgesic effects, and can be used for the study of chronic pain.

Anti-EPOR Antibody is a CHO-expressed human antibody targeting EPOR. Its predicted molecular weight (MW) is 150 kDa. For an isotype control, refer to Human IgG2 kappa, Isotype Control.

Anti-CD20 Antibody is a humanized antibody expressed in CHO cells, targeting CD20/MS4A1. It features a huIgG2SA heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa. For isotype control, refer to Human IgG2 kappa, Isotype Control.

AMG 317 is a humanized monoclonal antibody targeting CD124/IL4R/IL-4Rα. The recommended isotype control for this compound is HumanIgG2kappa, Isotype Control. It is applicable for research related to asthma.

CDX-1140 is a human IgG2 CD40 agonist antibody. It activates dendritic (DC) and B cells and induces NF-kB stimulation in CD40-expressing reporter cell lines. CDX-1140 functions independently of Fc receptor binding and works synergistically with natural CD40L signaling. It exhibits both direct and immune-mediated antitumor activity, making it useful for lymphoma and solid tumor research.

AMG-780 is a fully human IgG2 antibody targeting angiopoietin 1 (Ang1) with an IC50 of 4.5 nM and angiopoietin 2 (Ang2) with an IC50 of 0.06 nM. It inhibits tumor growth in Colo205 xenograft mouse models by suppressing Ang1 and Ang2. AMG-780 can be used in cancer research, such as for colorectal cancer.

RG-6125 is a humanized antibody expressed in CHO cells, targeting CDH11/Cadherin-11.